Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04482062 · ClinicalTrials.gov registry record · NA

TRISCEND II Pivotal Trial

A NA study of Heart Failure and Cardiovascular Diseases, sponsored by Edwards Lifesciences.

Active
Registry status
NA
Development phase
864
Enrollment target
20
Study locations

NCT04482062 is a NA study of Heart Failure and Cardiovascular Diseases that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 864 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04482062, a NA study of Heart Failure and Cardiovascular Diseases, is active but no longer recruiting, sponsored by Edwards Lifesciences.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
864 participants
Enrollment target
20
Study locations

Study Summary

Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system

Conditions Studied

Heart Failure Cardiovascular Diseases Heart Valve Diseases Tricuspid Valve Disease Tricuspid Valve Insufficiency Tricuspid Valve Regurgitation

Interventions

  • DRUG Optimal Medical Therapy
  • DEVICE Edwards EVOQUE System

Study Locations (20)

California

  • Scripps Memorial Hospital La Jolla - La Jolla
  • Cedars-Sinai Medical Center - Los Angeles
  • UC Davis Medical Center - Sacramento
  • Kaiser Permanente San Francisco - San Francisco
  • University of California San Francisco - San Francisco
  • Stanford University - Stanford

Florida

  • Florida Heart & Vascular Care - JFK - Atlantis
  • The Cardiac & Vascular Institute Research Foundation - Gainesville
  • NCH Heart Institute - Naples

Arizona

  • SJHMC Heart and Vascular Institute - Phoenix
  • Tucson Medical Center - Tucson

Georgia

  • Emory University - Atlanta
  • Piedmont Heart Institute - Atlanta

Kansas

  • Kansas University Medical Center - Kansas City
  • Ascension Via Christi St. Francis - Wichita

Colorado

  • Medical Center of the Rockies - Loveland

Illinois

  • Northwestern University - Chicago

Indiana

  • St. Vincent Heart Center of Indiana - Indianapolis

Trial Details

FieldValue
Enrollment Target 864 participants
Start Date 2021-04-09
Est. Completion 2030-06-27
Phase NA

Sponsor

Edwards Lifesciences

57 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04482062

The ClinicalTrials.gov registry entry for NCT04482062 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 864 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (58% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Optimal Medical Therapy is the first listed.

NCT04482062 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT04482062 about?

NCT04482062 is a clinical study titled "TRISCEND II Pivotal Trial". Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system

What is the current status of trial NCT04482062?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 864 participants. The study started on 2021-04-09. Estimated completion is 2030-06-27.

What conditions does trial NCT04482062 study?

This clinical trial studies the following conditions: Heart Failure, Cardiovascular Diseases, Heart Valve Diseases, Tricuspid Valve Disease, Tricuspid Valve Insufficiency.

What interventions are being tested in trial NCT04482062?

The interventions under investigation include: Optimal Medical Therapy (DRUG), Edwards EVOQUE System (DEVICE).

Who is sponsoring clinical trial NCT04482062?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04482062 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Cardiovascular Diseases

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.